Initial Experiences with a New 120 W Greenlight(TM) High-Power System for Photoselective Vaporization of the Prostate for the Treatment of Benign Prostatic Hyperplasia in Korea.
10.4111/kju.2009.50.11.1089
- Author:
Dong Woo KO
1
;
Byong Chang JEONG
;
Hwancheol SON
Author Information
1. Department of Urology, Seoul National University College of Medicine, Seoul, Korea. volley@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Prostatic hyperplasia;
Vaporization;
Lasers
- MeSH:
Catheterization;
Catheters;
Europe;
Hematuria;
Humans;
Korea;
Prostate;
Prostatic Hyperplasia;
Quality of Life;
Residual Volume;
Retrospective Studies;
United States;
Urinary Incontinence, Urge;
Urinary Tract Infections;
Volatilization
- From:Korean Journal of Urology
2009;50(11):1089-1094
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: After successful launches of a 120 W high-power system for photoselective vaporization of the prostate (HPS-PVP), several studies in the United States and Europe have reported good short-term data. Here we report the initial efficacy and side effects of the 120 W HPS-PVP in Korea. MATERIALS AND METHODS: Between January 2008 and January 2009, we performed a retrospective clinical analysis of 133 patients treated by HPS-PVP. RESULTS: The mean age at surgery was 68.4+/-8.0 years. The mean prostate size was 44.2+/-22.6 ml. The mean operation time was 58.9+/-33.5 minutes, and the mean total applied energy was 103,108+/-74,362 J. The mean duration of catheterization was 21.5+/-10.8 hours. The blood loss was minimal, and there were no transfusions. The baseline mean peak urinary flow rate (Qmax) was 10.4+/-5.0 ml/s, mean postvoid residual volume (PVR) was 77+/-91.3 ml, the mean International Prostate Symptom Score (IPSS) was 20.7+/-9.0, and the mean quality of life (QoL) score was 4.2+/-1.3. At 6 months, Qmax was 17.5+/-9.9 ml/sec, PVR was 49.0+/-56.0 ml, the IPSS was 8.0+/-9.0, and the QoL score was 1.6+/-1.5. During the first postoperative month, irritative urinary symptoms were reported in 18 cases, urge incontinence in 7, mild hematuria in 5, urinary tract infection in 2, and temporary recatheterization in 13. CONCLUSIONS: The new 120 W HPS-PVP showed good short-term safety and efficacy for the treatment of Korean patients with benign prostatic hyperplasia.
